Next Article in Journal
Does Exercise Improve False Episodic Memory in Dementia?
Previous Article in Journal
Multi-Site Photoplethysmography Technology for Blood Pressure Assessment: Challenges and Recommendations
Review

New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia

1
Departament of Nephrology, Jagiellonian University Medical College, Kopernika 15-15c, 31-501 Cracow, Poland
2
Department of Nephrology, Dialysis and Internal Medicine, Warsaw Medical University, Banacha 1a, 02-097 Warsaw, Poland
3
John Theurer Cancer Center, Hackensack University Medical Center, 92 2nd St, Hackensack, NJ 07601, USA
4
Departament of Hematology, Jagiellonian University Medical College, Kopernika 17, 30-501 Cracow, Poland
5
Departament of Clinical Medicine, Medical University, Szpitalna 37, 15-254 Bialystok, Poland
6
Departament of Nephrology, Medical University, Żurawia 14, 15-540 Bialystok, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2019, 8(11), 1828; https://doi.org/10.3390/jcm8111828
Received: 7 October 2019 / Revised: 28 October 2019 / Accepted: 29 October 2019 / Published: 1 November 2019
(This article belongs to the Section Nephrology & Urology)
Multiple myeloma (MM) is a malignancy of clonal plasma cells accounting for approximately 10% of haematological malignancies. MM mainly affects older patients, more often males and is more frequently seen in African Americans. The most frequent manifestations of MM are anaemia, osteolytic bone lesions, kidney failure and hypercalcemia. The anaemia develops secondary to suppression of erythropoiesis by cytokine networks, similarly to the mechanism of anaemia of chronic disease. The concomitant presence of kidney failure, especially chronic kidney disease (CKD) and MM per se, leading to anaemia of chronic disease (ACD) in combination, provoked us to pose the question about their reciprocal dependence and relationship with specific biomarkers; namely, soluble transferrin receptor (sTfR), growth differentiation factor 15 (GDF15), hepcidin 25 and zonulin. One or more of these are new biomarkers of ferric management may be utilized in the near future as prognostic predictors for patients with MM and kidney failure. View Full-Text
Keywords: anaemia; growth differentiation factor 15; hepcidin; kidney disease; mieloma multiple; soluble transferrin receptor; zonulin anaemia; growth differentiation factor 15; hepcidin; kidney disease; mieloma multiple; soluble transferrin receptor; zonulin
Show Figures

Figure 1

MDPI and ACS Style

Banaszkiewicz, M.; Małyszko, J.; Vesole, D.H.; Woziwodzka, K.; Jurczyszyn, A.; Żórawski, M.; Krzanowski, M.; Małyszko, J.; Batko, K.; Kuźniewski, M.; Krzanowska, K. New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. J. Clin. Med. 2019, 8, 1828. https://doi.org/10.3390/jcm8111828

AMA Style

Banaszkiewicz M, Małyszko J, Vesole DH, Woziwodzka K, Jurczyszyn A, Żórawski M, Krzanowski M, Małyszko J, Batko K, Kuźniewski M, Krzanowska K. New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia. Journal of Clinical Medicine. 2019; 8(11):1828. https://doi.org/10.3390/jcm8111828

Chicago/Turabian Style

Banaszkiewicz, Małgorzata, Jolanta Małyszko, David H. Vesole, Karolina Woziwodzka, Artur Jurczyszyn, Marcin Żórawski, Marcin Krzanowski, Jacek Małyszko, Krzysztof Batko, Marek Kuźniewski, and Katarzyna Krzanowska. 2019. "New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia" Journal of Clinical Medicine 8, no. 11: 1828. https://doi.org/10.3390/jcm8111828

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop